Tyr424
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus®
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Tyr424  -  Src (mouse)

Site Information
RLIEDNEytARQGAK   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 448234
Associated spectra:  2 CST

In vivo Characterization
Methods used to characterize site in vivo:
2D analysis ( 70 ) , [32P] bio-synthetic labeling ( 126 , 127 ) , immunoprecipitation ( 3 , 6 , 7 , 36 , 37 , 39 , 45 ) , mass spectrometry ( 7 , 8 , 11 , 13 , 15 , 17 , 18 , 19 , 27 , 33 , 34 , 35 , 38 , 43 , 44 , 46 , 48 , 50 , 51 , 52 , 53 , 54 , 55 , 56 , 58 , 60 , 63 , 65 , 67 , 68 , 71 , 73 , 74 , 75 , 76 , 77 , 78 , 79 , 80 , 81 , 82 , 83 , 84 , 85 , 86 , 87 , 88 , 89 , 90 , 92 , 93 , 94 , 96 , 98 , 99 , 100 , 101 , 102 , 103 , 104 , 105 , 106 , 107 , 108 , 109 , 110 , 112 , 113 , 115 , 116 , 117 , 118 , 119 , 120 ) , microscopy-colocalization with upstream kinase ( 6 ) , mutation of modification site ( 1 , 3 , 7 , 41 , 64 , 114 , 127 ) , phospho-antibody ( 2 , 3 , 4 , 5 , 6 , 7 , 9 , 10 , 12 , 20 , 21 , 22 , 23 , 25 , 28 , 29 , 30 , 31 , 32 , 36 , 37 , 39 , 40 , 41 , 42 , 45 , 47 , 49 , 57 , 61 , 62 , 64 , 66 , 69 , 70 , 72 , 91 , 95 , 97 , 111 , 121 , 122 , 123 , 124 , 125 ) , phosphopeptide mapping ( 126 , 127 ) , western blotting ( 1 , 2 , 3 , 4 , 5 , 6 , 7 , 9 , 10 , 12 , 20 , 21 , 22 , 23 , 25 , 28 , 29 , 30 , 31 , 32 , 36 , 37 , 39 , 40 , 41 , 42 , 45 , 47 , 49 , 57 , 61 , 62 , 64 , 66 , 69 , 70 , 72 , 111 , 121 , 122 )
Disease tissue studied:
lung cancer ( 1 , 58 ) , non-small cell lung cancer ( 33 , 58 ) , lymphoma ( 109 ) , neuroblastoma ( 10 ) , pancreatic cancer ( 20 ) , pancreatic carcinoma ( 20 ) , pituitary cancer ( 42 ) , melanoma skin cancer ( 21 ) , cancer, squamous cell carcinoma ( 23 )
Relevant cell line - cell type - tissue:
'3T3-L1, differentiated' (adipocyte) ( 8 ) , 'brain, cerebral cortex' ( 43 , 123 ) , 'brain, striatum' ( 41 ) , 'muscle, smooth'-thoracic aorta ( 64 ) , 'neuron, cortical'-brain ( 39 , 122 , 124 ) , 'renal, podocyte' ( 4 ) , 'stem, embryonic' ( 44 ) , 293 (epithelial) ( 1 , 61 , 64 , 122 , 125 ) , 293A (epithelial) ( 7 ) , 293F (epithelial) ( 5 , 47 ) , 32D (myeloid) [IRS1 (mouse)] ( 97 ) , 3T3 (fibroblast) ( 25 , 37 , 45 , 101 , 102 , 103 , 104 , 115 , 116 , 117 , 118 , 119 , 120 , 126 ) , 3T3 (fibroblast) [Pyk2 (human), transfection, stable Pyk2 (v5-His tagged) transfection, in RU-486 (mifepristone)-inducible expression system] ( 38 ) , 3T3 (fibroblast) [SHP-2 (mouse), homozygous knockout] ( 127 ) , 3T3 (fibroblast) [Src (human)] ( 108 ) , 3T3-L1 (fibroblast) ( 62 , 71 ) , 831/13 ( 112 , 113 ) , AB.1 (T lymphocyte) ( 30 ) , AtT20 (pituitary cell) ( 42 ) , B16 (melanocyte) ( 21 ) , BaF3 ('B lymphocyte, precursor') ( 73 , 74 , 75 , 76 , 77 , 78 , 79 , 80 , 81 , 82 , 83 , 84 , 85 , 86 , 87 , 88 , 89 , 90 , 92 , 93 , 94 , 96 , 110 ) , bone marrow ( 2 ) , brain ( 18 , 35 ) , C2C12 (myoblast) ( 50 , 51 , 52 , 53 , 54 , 55 ) , C3H10T1/2 (fibroblast) ( 66 ) , C4HD (breast cell) ( 91 ) , CL1-5 (pulmonary) ( 1 ) , colon ( 7 ) , COS (fibroblast) ( 69 ) , embryo ( 32 ) , FG (pancreatic) ( 20 ) , FL5.12 (lymphoid) ( 97 ) , GD25 (fibroblast) ( 121 ) , heart ( 15 ) , HeLa (cervical) ( 3 ) , HL-1 (myocyte) ( 13 ) , HL-1 (myocyte) [Akt1 (mouse), knockdown, stable lentiviral expression of Akt1 shRNA] ( 13 ) , HL-1 (myocyte) [Akt2 (mouse), knockdown, stable lentiviral expression of Akt2 shRNA] ( 13 ) , HUVEC (endothelial) ( 28 ) , keratinocyte-skin ( 47 ) , liver ( 17 , 63 ) , liver [leptin (mouse), homozygous knockout] ( 17 ) , lung ( 33 , 65 ) , macrophage ( 69 ) , MC3T3-E1 (preosteoblast) ( 36 ) , MCP-5 (mast) ( 60 ) , MEF (fibroblast) ( 3 , 32 , 48 , 56 , 57 , 61 , 67 , 69 , 72 ) , MEF (fibroblast) [p53 (mouse), homozygous knockout] ( 27 ) , MEF (fibroblast) [PTP1B (mouse), homozygous knockout] ( 48 ) , MEF (fibroblast) [PTPN2 (mouse), homozygous knockout] ( 49 ) , MEF (fibroblast) [Src (mouse)] ( 56 ) , megakaryocyte ( 31 ) , myocyte-heart ( 57 ) , Neuro-2a (neuron) ( 10 ) , neuron-'brain, hippocampus' ( 10 ) , neutrophil ( 40 ) , osteoblast ( 36 ) , osteoclast ( 114 ) , osteoclast-like cell ( 125 ) , PC-12 (chromaffin) ( 95 ) , prostate ( 22 ) , RAW 264.7 (macrophage) ( 6 , 11 ) , RAW 267.4 (macrophage) ( 46 ) , Sor4 ( 99 , 105 ) , Sor577 ( 98 , 107 ) , SorA ( 100 , 106 ) , spermatozoa ( 70 ) , spinal cord ( 29 ) , splenocyte-spleen ( 5 ) , squamous [FAK iso2 (mouse), homozygous knockout] ( 23 ) , Swiss 3T3 (fibroblast) ( 111 ) , SYF (fibroblast) ( 57 ) , SYF (fibroblast) [Src (mouse), transfection] ( 19 ) , T lymphocyte-lymph node ( 34 ) , vessel ( 12 ) , VSMC ( 12 )

Upstream Regulation
Regulatory protein:
ACF7 (mouse) ( 47 ) , AR (mouse) ( 22 ) , CD44 (mouse) ( 69 ) , CD74 (mouse) ( 69 ) , DNAJB4 (human) ( 1 ) , ERG (mouse) ( 22 ) , FAK iso2 (mouse) ( 23 , 32 ) , GAB2 (mouse) ( 2 ) , GPM6A (human) ( 10 ) , GRK5 (mouse) ( 64 ) , Israa (mouse) ( 5 ) , Klra17 (mouse) ( 40 ) , KOR-1 (mouse) ( 42 ) , KRas (mouse) ( 22 ) , PPP2CA (human) ( 31 ) , PTPN2 (human) ( 49 ) , PTPN2 (mouse) ( 49 ) , PTPRA (human) ( 59 ) , PTPRA (mouse) ( 72 ) , RHOC (mouse) ( 21 ) , Src (mouse) ( 19 , 21 , 56 )
Kinases, in vitro:
Src (human) ( 61 ) , Src (mouse) ( 126 )
Putative upstream phosphatases:
PTPN2 (mouse) ( 6 )
Phosphatases, in vitro:
PTPN2 (mouse) ( 6 )
Treatments:
1-butanol ( 95 ) , 1Na-PP1 ( 39 ) , angiotensin_2 ( 12 ) , anti-CD3 ( 5 , 34 ) , anti-vitronectin ( 125 ) , aphidicolin ( 49 ) , BDNF ( 39 ) , caffeine ( 49 ) , calmidazolium ( 122 ) , cAMP_analog ( 70 ) , cell_adhesion ( 47 ) , chloroquine ( 23 ) , colforsin ( 29 ) , CPCCOEt ( 122 ) , dasatinib ( 23 , 36 ) , dexamethasone ( 66 ) , DHPG ( 122 ) , EGF ( 20 , 45 , 66 , 95 ) , epoxomicin ( 23 ) , estradiol ( 123 ) , fibronectin ( 59 ) , fMLP ( 40 ) , forced swim test ( 41 ) , Freund's_complete_adjuvant ( 29 ) , GF109203X ( 62 , 122 ) , H-89 ( 29 , 70 ) , H2O2 ( 30 , 57 , 72 , 95 ) , high-fat diet ( 25 ) , IBMX ( 66 ) , IGF-1 ( 20 ) , imatinib ( 97 ) , ionomycin ( 30 ) , LPS ( 6 ) , MIF ( 69 ) , mifepristone ( 91 ) , MK801 ( 122 ) , MMS ( 49 ) , MPA ( 91 , 97 ) , MPEP ( 122 ) , MSP ( 20 ) , nocodazole ( 37 ) , ophiobolin ( 122 ) , osmotic_stress ( 111 ) , palmitate ( 25 ) , palmitoleic_acid ( 25 ) , PDGF ( 57 , 62 , 64 ) , phorbol_ester ( 57 , 122 ) , PKCI_19-27 ( 122 ) , polyunsaturated_fatty_acid ( 25 ) , PP1 ( 39 , 57 ) , PP2 ( 66 , 69 , 91 , 95 , 123 ) , PTX ( 70 ) , saturated_fatty_acid ( 25 ) , serum_starvation ( 61 ) , SU6656 ( 12 , 49 ) , t-butanol ( 95 ) , TCDD ( 66 ) , thapsigargin ( 30 ) , thymidine ( 49 ) , U50488 ( 42 ) , UV ( 49 ) , vanadate ( 127 ) , W-7 ( 122 ) , Zn(2+) ( 39 )

Downstream Regulation
Effects of modification on Src:
activity, induced ( 127 ) , enzymatic activity, induced ( 114 ) , molecular association, regulation ( 123 )
Effects of modification on biological processes:
cell differentiation, altered ( 36 ) , cytoskeletal reorganization ( 114 )
Induce interaction with:
GRB2 (mouse) ( 123 )

References 

1

Chen CH, et al. (2016) HLJ1 is an endogenous Src inhibitor suppressing cancer progression through dual mechanisms. Oncogene 35, 5674-5685
27065329   Curated Info

2

Gu S, et al. (2016) Distinct GAB2 signaling pathways are essential for myeloid and lymphoid transformation and leukemogenesis by BCR-ABL1. Blood 127, 1803-13
26773044   Curated Info

3

Liu X, et al. (2016) Gain-of-function mutations of Ptpn11 (Shp2) cause aberrant mitosis and increase susceptibility to DNA damage-induced malignancies. Proc Natl Acad Sci U S A 113, 984-9
26755576   Curated Info

4

Verma R, et al. (2016) Integrin Ligation Results in Nephrin Tyrosine Phosphorylation In Vitro. PLoS One 11, e0148906
26848974   Curated Info

5

Ben Khalaf N, Taha S, Bakhiet M, Fathallah MD (2016) A Central Nervous System-Dependent Intron-Embedded Gene Encodes a Novel Murine Fyn Binding Protein. PLoS One 11, e0149612
26901312   Curated Info

6

Ha Thi HT, et al. (2016) Protein Tyrosine Phosphatase N2 Is a Positive Regulator of Lipopolysaccharide Signaling in Raw264.7 Cell through Derepression of Src Tyrosine Kinase. PLoS One 11, e0162724
27611995   Curated Info

7

Murata Y, et al. (2015) Protein tyrosine phosphatase SAP-1 protects against colitis through regulation of CEACAM20 in the intestinal epithelium. Proc Natl Acad Sci U S A 112, E4264-71
26195794   Curated Info

8

Parker BL, et al. (2015) Targeted phosphoproteomics of insulin signaling using data-independent acquisition mass spectrometry. Sci Signal 8, rs6
26060331   Curated Info

9

Beristain AG, et al. (2015) PKA signaling drives mammary tumorigenesis through Src. Oncogene 34, 1160-73
24662820   Curated Info

10

Formoso K, Billi SC, Frasch AC, Scorticati C (2015) Tyrosine 251 at the C-terminus of neuronal glycoprotein M6a is critical for neurite outgrowth. J Neurosci Res 93, 215-29
25242528   Curated Info

11

Pinto SM, et al. (2015) Quantitative phosphoproteomic analysis of IL-33-mediated signaling. Proteomics 15, 532-44
25367039   Curated Info

12

Qin B, Zhou J (2015) Src Family Kinases (SFK) Mediate Angiotensin II-Induced Myosin Light Chain Phosphorylation and Hypertension. PLoS One 10, e0127891
26011449   Curated Info

13

Reinartz M, Raupach A, Kaisers W, Gödecke A (2014) AKT1 and AKT2 induce distinct phosphorylation patterns in HL-1 cardiac myocytes. J Proteome Res 13, 4232-45
25162660   Curated Info

14

Mertins P, et al. (2014) Ischemia in tumors induces early and sustained phosphorylation changes in stress kinase pathways but does not affect global protein levels. Mol Cell Proteomics 13, 1690-704
24719451   Curated Info

15

Lundby A, et al. (2013) In vivo phosphoproteomics analysis reveals the cardiac targets of β-adrenergic receptor signaling. Sci Signal 6, rs11
23737553   Curated Info

16

Yu L, et al. (2013) Inhibition of nephrin activation by c-mip through Csk-Cbp-Fyn axis plays a critical role in Angiotensin II-induced podocyte damage. Cell Signal 25, 581-8
23200848   Curated Info

17

Grimsrud PA, et al. (2012) A quantitative map of the liver mitochondrial phosphoproteome reveals posttranslational control of ketogenesis. Cell Metab 16, 672-83
23140645   Curated Info

18

Trinidad JC, et al. (2012) Global identification and characterization of both O-GlcNAcylation and phosphorylation at the murine synapse. Mol Cell Proteomics 11, 215-29
22645316   Curated Info

19

Ferrando IM, et al. (2012) Identification of targets of c-Src tyrosine kinase by chemical complementation and phosphoproteomics. Mol Cell Proteomics 11, 355-69
22499769   Curated Info

20

Huang M, et al. (2012) EGFR-dependent pancreatic carcinoma cell metastasis through Rap1 activation. Oncogene 31, 2783-93
21963850   Curated Info

21

Arpaia E, et al. (2012) The interaction between caveolin-1 and Rho-GTPases promotes metastasis by controlling the expression of alpha5-integrin and the activation of Src, Ras and Erk. Oncogene 31, 884-96
21765460   Curated Info

22

Drake JM, et al. (2012) Oncogene-specific activation of tyrosine kinase networks during prostate cancer progression. Proc Natl Acad Sci U S A 109, 1643-8
22307624   Curated Info

23

Sandilands E, et al. (2012) Autophagic targeting of Src promotes cancer cell survival following reduced FAK signalling. Nat Cell Biol 14, 51-60
22138575   Curated Info

24

Miharada K, et al. (2011) Cripto regulates hematopoietic stem cells as a hypoxic-niche-related factor through cell surface receptor GRP78. Cell Stem Cell 9, 330-44
21982233   Curated Info

25

Holzer RG, et al. (2011) Saturated fatty acids induce c-Src clustering within membrane subdomains, leading to JNK activation. Cell 147, 173-84
21962514   Curated Info

26

Oneyama C, et al. (2011) MicroRNA-mediated downregulation of mTOR/FGFR3 controls tumor growth induced by Src-related oncogenic pathways. Oncogene 30, 3489-501
21383697   Curated Info

27

Hsu PP, et al. (2011) The mTOR-regulated phosphoproteome reveals a mechanism of mTORC1-mediated inhibition of growth factor signaling. Science 332, 1317-22
21659604   Curated Info

28

Xu K, et al. (2011) Blood vessel tubulogenesis requires Rasip1 regulation of GTPase signaling. Dev Cell 20, 526-39
21396893   Curated Info

29

Yang HB, et al. (2011) cAMP-dependent protein kinase activated Fyn in spinal dorsal horn to regulate NMDA receptor function during inflammatory pain. J Neurochem 116, 93-104
21054385   Curated Info

30

Lysechko TL, Cheung SM, Ostergaard HL (2010) Regulation of the tyrosine kinase Pyk2 by calcium is through production of reactive oxygen species in cytotoxic T lymphocytes. J Biol Chem 285, 31174-84
20688918   Curated Info

31

Pradhan S, et al. (2010) Cross-talk between serine/threonine protein phosphatase 2A and protein tyrosine phosphatase 1B regulates Src activation and adhesion of integrin αIIbβ3 to fibrinogen. J Biol Chem 285, 29059-68
20615878   Curated Info

32

Lim ST, et al. (2010) Knock-in mutation reveals an essential role for focal adhesion kinase activity in blood vessel morphogenesis and cell motility-polarity but not cell proliferation. J Biol Chem 285, 21526-36
20442405   Curated Info

33

Carretero J, et al. (2010) Integrative genomic and proteomic analyses identify targets for Lkb1-deficient metastatic lung tumors. Cancer Cell 17, 547-59
20541700   Curated Info

34

Iwai LK, Benoist C, Mathis D, White FM (2010) Quantitative phosphoproteomic analysis of T cell receptor signaling in diabetes prone and resistant mice. J Proteome Res 9, 3135-45
20438120   Curated Info

35

Wiśniewski JR, et al. (2010) Brain phosphoproteome obtained by a FASP-based method reveals plasma membrane protein topology. J Proteome Res 9, 3280-9
20415495   Curated Info

36

Lee YC, et al. (2010) Src family kinase/abl inhibitor dasatinib suppresses proliferation and enhances differentiation of osteoblasts. Oncogene 29, 3196-207
20228840   Curated Info

37

Vacaru AM, den Hertog J (2010) Serine Dephosphorylation of Receptor Protein Tyrosine Phosphatase {alpha} in Mitosis Induces Src Binding and Activation. Mol Cell Biol 30, 2850-61
20385765   Curated Info

38

Bonnette PC, et al. (2010) Phosphoproteomic characterization of PYK2 signaling pathways involved in osteogenesis. J Proteomics 73, 1306-20
20116462   Curated Info

39

Huang YZ, McNamara JO (2010) Mutual regulation of Src family kinases and the neurotrophin receptor TrkB. J Biol Chem 285, 8207-17
20064930   Curated Info

40

Sasawatari S, et al. (2010) The Ly49Q receptor plays a crucial role in neutrophil polarization and migration by regulating raft trafficking. Immunity 32, 200-13
20153219   Curated Info

41

Taniguchi S, et al. (2009) Involvement of NMDAR2A tyrosine phosphorylation in depression-related behaviour. EMBO J 28, 3717-29
19834457   Curated Info

42

Clayton CC, Xu M, Chavkin C (2009) Tyrosine phosphorylation of Kir3 following kappa-opioid receptor activation of p38 MAPK causes heterologous desensitization. J Biol Chem 284, 31872-81
19773548   Curated Info

43

Tweedie-Cullen RY, Reck JM, Mansuy IM (2009) Comprehensive mapping of post-translational modifications on synaptic, nuclear, and histone proteins in the adult mouse brain. J Proteome Res 8, 4966-82
19737024   Curated Info

44

Li H, et al. (2009) SysPTM: a systematic resource for proteomic research on post-translational modifications. Mol Cell Proteomics 8, 1839-49
19366988   Curated Info

45

Chung BM, et al. (2009) The role of cooperativity with Src in oncogenic transformation mediated by non-small cell lung cancer-associated EGF receptor mutants. Oncogene 28, 1821-32
19305428   Curated Info

46

Trost M, et al. (2009) The phagosomal proteome in interferon-gamma-activated macrophages. Immunity 30, 143-54
19144319   Curated Info

47

Wu X, Kodama A, Fuchs E (2008) ACF7 regulates cytoskeletal-focal adhesion dynamics and migration and has ATPase activity. Cell 135, 137-48
18854161   Curated Info

48

Mertins P, et al. (2008) Investigation of protein-tyrosine phosphatase 1B function by quantitative proteomics. Mol Cell Proteomics 7, 1763-77
18515860   Curated Info

49

Shields BJ, et al. (2008) DNA replication stalling attenuates tyrosine kinase signaling to suppress S phase progression. Cancer Cell 14, 166-79
18691551   Curated Info

50

Possemato A (2008) CST Curation Set: 4931; Year: 2008; Biosample/Treatment: cell line, C2C12/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

51

Possemato A (2008) CST Curation Set: 4932; Year: 2008; Biosample/Treatment: cell line, C2C12/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

52

Possemato A (2008) CST Curation Set: 4933; Year: 2008; Biosample/Treatment: cell line, C2C12/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

53

Possemato A (2008) CST Curation Set: 4934; Year: 2008; Biosample/Treatment: cell line, C2C12/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

54

Possemato A (2008) CST Curation Set: 4935; Year: 2008; Biosample/Treatment: cell line, C2C12/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

55

Possemato A (2008) CST Curation Set: 4929; Year: 2008; Biosample/Treatment: cell line, C2C12/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

56

Luo W, et al. (2008) Global impact of oncogenic Src on a phosphotyrosine proteome. J Proteome Res 7, 3447-60
18563927   Curated Info

57

Rybin VO, et al. (2008) Phorbol 12-myristate 13-acetate-dependent protein kinase C delta-Tyr311 phosphorylation in cardiomyocyte caveolae. J Biol Chem 283, 17777-88
18387943   Curated Info

58

Rikova K (2008) CST Curation Set: 4252; Year: 2008; Biosample/Treatment: tissue, lung/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

59

Wu L, et al. (2008) Distinct FAK-Src activation events promote alpha5beta1 and alpha4beta1 integrin-stimulated neuroblastoma cell motility. Oncogene 27, 1439-48
17828307   Curated Info

60

Cao L, et al. (2007) Quantitative time-resolved phosphoproteomic analysis of mast cell signaling. J Immunol 179, 5864-76
17947660   Curated Info

61

Radziwill G, et al. (2007) Regulation of c-Src by binding to the PDZ domain of AF-6. EMBO J 26, 2633-44
17491594   Curated Info

62

Artemenko Y, Gagnon A, Ibrahim S, Sorisky A (2007) Regulation of PDGF-stimulated SHIP2 tyrosine phosphorylation and association with Shc in 3T3-L1 preadipocytes. J Cell Physiol 211, 598-607
17219406   Curated Info

63

Villén J, Beausoleil SA, Gerber SA, Gygi SP (2007) Large-scale phosphorylation analysis of mouse liver. Proc Natl Acad Sci U S A 104, 1488-93
17242355   Curated Info

64

Wu JH, et al. (2006) Regulation of the platelet-derived growth factor receptor-beta by G protein-coupled receptor kinase-5 in vascular smooth muscle cells involves the phosphatase Shp2. J Biol Chem 281, 37758-72
17018529   Curated Info

65

Farnsworth C (2006) CST Curation Set: 2094; Year: 2006; Biosample/Treatment: tissue, lung/-; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

66

Liu X, Jefcoate C (2006) 2,3,7,8-tetrachlorodibenzo-p-dioxin and epidermal growth factor cooperatively suppress peroxisome proliferator-activated receptor-gamma1 stimulation and restore focal adhesion complexes during adipogenesis: selective contributions of Src, Rho, and Erk distinguish these overlapping processes in C3H10T1/2 cells. Mol Pharmacol 70, 1902-15
16971554   Curated Info

67

Li Y (2006) CST Curation Set: 2049; Year: 2006; Biosample/Treatment: cell line, MEF/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

68

Zhou J (2006) CST Curation Set: 1969; Year: 2006; Biosample1/Treatment/Isotope: tissue, brain/untreated/L, Biosample2/Treatment/Isotope: tissue, brain/untreated/H; Disease: -; SILAC: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: YXp[ST]
Curated Info

69

Shi X, et al. (2006) CD44 is the signaling component of the macrophage migration inhibitory factor-CD74 receptor complex. Immunity 25, 595-606
17045821   Curated Info

70

Baker MA, Hetherington L, Aitken RJ (2006) Identification of SRC as a key PKA-stimulated tyrosine kinase involved in the capacitation-associated hyperactivation of murine spermatozoa. J Cell Sci 119, 3182-92
16835269   Curated Info

71

Schmelzle K, et al. (2006) Temporal dynamics of tyrosine phosphorylation in insulin signaling. Diabetes 55, 2171-9
16873679   Curated Info

72

Hao Q, Rutherford SA, Low B, Tang H (2006) Selective regulation of hydrogen peroxide signaling by receptor tyrosine phosphatase-alpha. Free Radic Biol Med 41, 302-10
16814111   Curated Info

73

Goss V (2006) CST Curation Set: 1403; Year: 2006; Biosample/Treatment: cell line, BaF3/-; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

74

Goss V (2006) CST Curation Set: 1404; Year: 2006; Biosample/Treatment: cell line, BaF3/serum starved &'||' IL3 starvation &'||' Tpo; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

75

Goss V (2006) CST Curation Set: 1405; Year: 2006; Biosample1/Treatment/Isotope: cell line, BaF3/none/L, Biosample2/Treatment/Isotope: cell line, BaF3/none/H; Disease: chronic myelogenous leukemia; SILAC: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

76

Goss V (2006) CST Curation Set: 1406; Year: 2006; Biosample1/Treatment/Isotope: cell line, BaF3/serum starved &'||' IL3 starvation &'||' Tpo/L, Biosample2/Treatment/Isotope: cell line, BaF3/serum starved &'||' IL3 starvation &'||' Tpo/H; Disease: chronic myelogenous leukemia; SILAC: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

77

Gu T (2006) CST Curation Set: 1311; Year: 2006; Biosample/Treatment: cell line, BaF3/-; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

78

Goss V (2006) CST Curation Set: 1200; Year: 2006; Biosample/Treatment: cell line, BaF3/-; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

79

Gu T (2005) CST Curation Set: 1058; Year: 2005; Biosample/Treatment: cell line, BaF3/-; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

80

Goss V (2005) CST Curation Set: 861; Year: 2005; Biosample/Treatment: cell line, BaF3/-; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

81

Goss V (2005) CST Curation Set: 862; Year: 2005; Biosample/Treatment: cell line, BaF3/-; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

82

Goss V (2005) CST Curation Set: 847; Year: 2005; Biosample/Treatment: cell line, BaF3/serum starved; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

83

Goss V (2005) CST Curation Set: 848; Year: 2005; Biosample/Treatment: cell line, BaF3/serum starved; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

84

Gu T (2005) CST Curation Set: 844; Year: 2005; Biosample/Treatment: cell line, BaF3/-; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

85

Gu T (2005) CST Curation Set: 845; Year: 2005; Biosample/Treatment: cell line, BaF3/-; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

86

Gu T (2005) CST Curation Set: 846; Year: 2005; Biosample/Treatment: cell line, BaF3/-; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

87

Goss V (2005) CST Curation Set: 814; Year: 2005; Biosample/Treatment: cell line, BaF3/-; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

88

Goss V (2005) CST Curation Set: 813; Year: 2005; Biosample/Treatment: cell line, BaF3/-; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

89

Goss V (2005) CST Curation Set: 815; Year: 2005; Biosample/Treatment: cell line, BaF3/-; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

90

Goss V (2005) CST Curation Set: 816; Year: 2005; Biosample/Treatment: cell line, BaF3/-; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

91

Proietti C, et al. (2005) Progestins induce transcriptional activation of signal transducer and activator of transcription 3 (Stat3) via a Jak- and Src-dependent mechanism in breast cancer cells. Mol Cell Biol 25, 4826-40
15923602   Curated Info

92

Goss V (2005) CST Curation Set: 698; Year: 2005; Biosample/Treatment: cell line, BaF3/-; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

93

Gu T (2005) CST Curation Set: 699; Year: 2005; Biosample/Treatment: cell line, BaF3/-; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

94

Gu T (2005) CST Curation Set: 700; Year: 2005; Biosample/Treatment: cell line, BaF3/-; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

95

Banno Y, et al. (2005) Implication of phospholipase D2 in oxidant-induced phosphoinositide 3-kinase signaling via Pyk2 activation in PC12 cells. J Biol Chem 280, 16319-24
15705590   Curated Info

96

Goss V (2005) CST Curation Set: 670; Year: 2005; Biosample/Treatment: cell line, BaF3/serum starved &'||' Tpo; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

97

Gu JJ, Santiago L, Mitchell BS (2005) Synergy between imatinib and mycophenolic acid in inducing apoptosis in cell lines expressing Bcr-Abl. Blood 105, 3270-7
15604220   Curated Info

98

Boccalatte F (2005) CST Curation Set: 635; Year: 2005; Biosample/Treatment: cell line, Sor577/-; Disease: lymphoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

99

Boccalatte F (2005) CST Curation Set: 636; Year: 2005; Biosample/Treatment: cell line, Sor4/-; Disease: lymphoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

100

Boccalatte F (2005) CST Curation Set: 637; Year: 2005; Biosample/Treatment: cell line, SorA/-; Disease: lymphoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

101

Guo A (2005) CST Curation Set: 629; Year: 2005; Biosample/Treatment: cell line, 3T3/serum starved; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

102

Guo A (2005) CST Curation Set: 630; Year: 2005; Biosample/Treatment: cell line, 3T3/EGF; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

103

Guo A (2005) CST Curation Set: 631; Year: 2005; Biosample/Treatment: cell line, 3T3/serum starved; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

104

Guo A (2005) CST Curation Set: 633; Year: 2005; Biosample/Treatment: cell line, 3T3/serum starved; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

105

Boccalatte F (2005) CST Curation Set: 566; Year: 2005; Biosample/Treatment: cell line, Sor4/-; Disease: lymphoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

106

Boccalatte F (2005) CST Curation Set: 567; Year: 2005; Biosample/Treatment: cell line, SorA/-; Disease: lymphoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

107

Boccalatte F (2005) CST Curation Set: 568; Year: 2005; Biosample/Treatment: cell line, Sor577/-; Disease: lymphoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

108

Rush J, et al. (2005) Immunoaffinity profiling of tyrosine phosphorylation in cancer cells. Nat Biotechnol 23, 94-101
15592455   Curated Info

109

Boccalatte F (2004) CST Curation Set: 500; Year: 2004; Biosample/Treatment: cell line, Tg 543/-; Disease: lymphoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

110

Goss V (2004) CST Curation Set: 496; Year: 2004; Biosample/Treatment: cell line, BaF3/serum starved; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

111

Lunn JA, Rozengurt E (2004) Hyperosmotic stress induces rapid focal adhesion kinase phosphorylation at tyrosines 397 and 577. Role of Src family kinases and Rho family GTPases. J Biol Chem 279, 45266-78
15302877   Curated Info

112

Li Y (2004) CST Curation Set: 381; Year: 2004; Biosample/Treatment: cell line, 831/13/Serum starved &'||' IGF; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

113

Li Y (2004) CST Curation Set: 382; Year: 2004; Biosample/Treatment: cell line, 831/13/Serum starved &'||' Insulin; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

114

Miyazaki T, et al. (2004) Src kinase activity is essential for osteoclast function. J Biol Chem 279, 17660-6
14739300   Curated Info

115

Moritz A (2004) CST Curation Set: 265; Year: 2004; Biosample/Treatment: cell line, 3T3/serum starved; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

116

Moritz A (2003) CST Curation Set: 206; Year: 2003; Biosample/Treatment: cell line, 3T3/NRG1; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

117

Moritz A (2003) CST Curation Set: 209; Year: 2003; Biosample/Treatment: cell line, 3T3/NRG1; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

118

Moritz A (2003) CST Curation Set: 150; Year: 2003; Biosample/Treatment: cell line, 3T3/-; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

119

Moritz A (2003) CST Curation Set: 151; Year: 2003; Biosample/Treatment: cell line, 3T3/-; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

120

Moritz A (2003) CST Curation Set: 90; Year: 2003; Biosample/Treatment: cell line, 3T3/-; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

121

Pankov R, et al. (2003) Specific beta1 integrin site selectively regulates Akt/protein kinase B signaling via local activation of protein phosphatase 2A. J Biol Chem 278, 18671-81
12637511   Curated Info

122

Heidinger V, et al. (2002) Metabotropic glutamate receptor 1-induced upregulation of NMDA receptor current: mediation through the Pyk2/Src-family kinase pathway in cortical neurons. J Neurosci 22, 5452-61
12097497   Curated Info

123

Nethrapalli IS, et al. (2001) Estradiol (E2) elicits SRC phosphorylation in the mouse neocortex: the initial event in E2 activation of the MAPK cascade? Endocrinology 142, 5145-8
11713208   Curated Info

124

Manzerra P, et al. (2001) Zinc induces a Src family kinase-mediated up-regulation of NMDA receptor activity and excitotoxicity. Proc Natl Acad Sci U S A 98, 11055-61
11572968   Curated Info

125

Sanjay A, et al. (2001) Cbl associates with Pyk2 and Src to regulate Src kinase activity, alpha(v)beta(3) integrin-mediated signaling, cell adhesion, and osteoclast motility. J Cell Biol 152, 181-95
11149930   Curated Info

126

Pu M, et al. (1996) Evidence of a novel redox-linked activation mechanism for the Src kinase which is independent of tyrosine 527-mediated regulation. Oncogene 13, 2615-22
9000135   Curated Info

127

Kmiecik TE, Johnson PJ, Shalloway D (1988) Regulation by the autophosphorylation site in overexpressed pp60c-src. Mol Cell Biol 8, 4541-6
2460746   Curated Info